Savara (NASDAQ:SVRA) Trading Down 5.1% – Here’s Why

Savara Inc. (NASDAQ:SVRA) dropped 5.1% during mid-day trading on Tuesday . The stock traded as low as $6.05 and last traded at $6.0070. Approximately 901,501 shares changed hands during trading, a decline of 43% from the average daily volume of 1,587,894 shares. The stock had previously closed at $6.33.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SVRA shares. JMP Securities raised their price target on shares of Savara from $8.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. Lifesci Capital upgraded shares of Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. UBS Group set a $10.00 price objective on shares of Savara in a research report on Tuesday, December 23rd. Finally, Guggenheim restated a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.13.

Savara Stock Down 1.3%

The stock has a 50-day moving average of $5.35 and a two-hundred day moving average of $3.80. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The company has a market cap of $1.23 billion, a P/E ratio of -11.38 and a beta of 0.23.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, research analysts anticipate that Savara Inc. will post -0.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SVRA. Sivia Capital Partners LLC boosted its holdings in shares of Savara by 9.1% in the 2nd quarter. Sivia Capital Partners LLC now owns 41,500 shares of the company’s stock valued at $95,000 after buying an additional 3,459 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Savara by 52.3% during the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after purchasing an additional 4,626 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Savara by 17.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock valued at $87,000 after purchasing an additional 5,687 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Savara by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after purchasing an additional 6,449 shares in the last quarter. Finally, Sio Capital Management LLC increased its position in Savara by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 726,851 shares of the company’s stock valued at $1,657,000 after buying an additional 7,197 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.